What NovaCell Technology does

NovaCell Technology Inc. is a South Korean private biotherapeutics company headquartered on the POSTECH campus in Pohang, specializing in peptide-based drug candidates and biomaterials. The company's core technology platform targets FPR2 (Formyl Peptide Receptor 2) with activating peptides designed to promote the body's natural inflammation-resolution process, in contrast to conventional anti-inflammatory approaches that primarily suppress inflammation. Its lead asset, HUC1-394, is a peptide-based ophthalmic solution for dry eye disease that has secured IND approval from South Korea's Ministry of Food and Drug Safety and entered Phase 2 clinical trials under licensee Huons.

NovaCell operates as a technology licensor and pipeline developer rather than a vertically integrated commercial pharmaceutical company. Its primary go-to-market motion is out-licensing proprietary peptide candidates to pharmaceutical partners — most notably the Huons agreement for HUC1-394 — for clinical development and commercialization, generating licensing fees with potential milestone and royalty upside. The company also operates a consumer sub-brand, Novapet, distributed through nationwide pharmacy channels in South Korea. Revenue mechanics are not publicly disclosed, and the company is pursuing a pre-IPO listing with associated capital-raising and reporting milestones active in 2026.

The company's customer base is concentrated in pharmaceutical partners (Huons) and clinical sites (Severance Hospital / Yonsei University College of Medicine for the Phase 2 trial). NovaCell is founder-led under CEO Lee Tae-hoon and has raised approximately $11.16M in disclosed equity funding led by Quantum Ventures Korea with participation from Korea Investment Partners, Huons, Aion Investment Management, and other Korean venture investors. Strategic positioning centers on a differentiated FPR2 mechanism-of-action platform with potential applications across ophthalmology, immunology, and broader inflammatory indications.

Name

NovaCell Technology

Legal name

NOVACELL TECHNOLOGY Inc.

Website

https://novacelltech.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

NovaCell Technology is a South Korean private biotherapeutics company developing FPR2-targeting peptide drug candidates, with lead asset HUC1-394 in Phase 2 trials for dry eye disease. It operates as a technology licensor to pharmaceutical partners such as Huons and is pursuing a pre-IPO listing.

Ownership category

akta.pro rank

Product category

Peptide-based Biotherapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Peptide biotherapeutics
• Ophthalmic drug development
• Dry eye disease treatment
• FPR2 targeting peptides
• Inflammation resolution therapeutics

Headquarters

HQ city

Pohang

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Technology Licensing: NovaCell generates revenue by licensing its proprietary peptide technology and drug candidates to pharmaceutical companies. The company licensed HUC1-394 (dry eye treatment) to Huons for clinical development and commercialization, receiving licensing fees and potentially milestone payments and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

NovaCell Technology develops proprietary peptide-based biotherapeutics with a focus on FPR2 (Formyl Peptide Receptor 2) targeting peptides that promote the body's natural inflammation-resolution process. Its lead clinical candidate, HUC1-394, is a peptide-based ophthalmic solution for dry eye disease, currently licensed to Huons for Phase 2 clinical trials in South Korea. The company additionally markets a pet-health product line under the Novapet brand through nationwide pharmacy channels.

Product overview

NovaCell Technology is a global peptide-based biotherapeutics and biomaterial company. The company's core offering is its pipeline of peptide-based drug candidates, with HUC1-394 being the lead candidate — a peptide-based ophthalmic solution for dry eye disease that works through a novel FPR2-mediated inflammation-resolution mechanism. The company operates primarily in the pharmaceutical development space, with ongoing clinical trials and pre-IPO activities.

Differentiator

Problem solved

Functional benefit

Products and services

• HUC1-394 Peptide-based ophthalmic solution for dry eye disease. The novel mechanism works by activating FPR2 (Formyl Peptide Receptor 2) to promote the body's natural inflammation-resolution process, offering a differentiated approach compared to conventional treatments that mainly suppress inflammation. Licensed to Huons for Phase 2 clinical development in South Korea, with trials involving approximately 150 patients at sites including Severance Hospital (Yonsei University College of Medicine).
• Novapet (brand product line) Consumer pet-health product line marketed under the Novapet brand, leveraging NovaCell's peptide-based biomaterials and biotherapeutics platform. Distributed nationwide through South Korean pharmacy retail channels.

Quantifiable outcome

• HUC1-394 peptide-based ophthalmic solution demonstrating novel mechanism in Phase 2 clinical trials for dry eye disease

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• HuonscoreTechnology or Integration · 12 March 2026NovaCell Technology licensed its HUC1-394 peptide-based dry eye treatment candidate to Huons. Huons received Investigational New Drug (IND) approval from South Korea's Ministry of Food and Drug Safety to begin Phase 2 clinical trials for this dry eye treatment. The licensing agreement allows Huons to develop and commercialize the product in South Korea.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Bausch + Lomb: Global ophthalmic pharmaceutical and device company with established dry eye and ocular surface disease franchises. Broad incumbent operating in the same end market as NovaCell and representing a likely global commercialization partner for differentiated ophthalmic assets.
• Aerie Pharmaceuticals: Ophthalmic specialty pharmaceutical company focused on novel therapies for glaucoma and other eye diseases (now part of Alcon). Broad incumbent comparable to NovaCell given similar specialty ophthalmology positioning and partner-driven commercial model.

Direct peers

• Ocular Therapeutix: Clinical-stage biopharmaceutical company developing novel ophthalmic therapeutics, including dry eye disease candidates, with a focus on drug delivery innovation. Direct peer to NovaCell given parallel positioning in differentiated dry eye therapeutics development.
• Novaliq: Specialty ophthalmic pharmaceutical company developing novel water-free drug delivery solutions for dry eye and other ocular surface diseases. Direct peer to NovaCell in the differentiated dry eye therapeutics space with similar licensing-driven commercialization approach.
• Kala Bio: Clinical-stage ophthalmic specialty company developing novel therapies for rare and serious eye diseases. Comparable to NovaCell as a small-cap clinical-stage ophthalmology company pursuing differentiated mechanisms with licensing partnerships.
• Aldeyra Therapeutics: Clinical-stage biotech developing novel mechanisms for inflammatory eye diseases, including dry eye disease (reproxalap). Direct peer to NovaCell given the shared focus on differentiated inflammation-targeting ophthalmology therapeutics and Phase-stage development model.

Regional players

• HanAll Biopharma: South Korean biopharmaceutical company with ophthalmology and immunology pipeline assets, including biosimilars and novel therapeutics. Comparable to NovaCell as a Korean regional peer pursuing innovative ophthalmic and inflammatory disease treatments.
• Huons Global: South Korean pharmaceutical company with established ophthalmic and injectable product lines. Both a strategic partner (licensing HUC1-394) and a regional comparable to NovaCell given parallel presence in Korean ophthalmic specialty pharma.
• Yuyu Pharma: South Korean pharmaceutical company with ophthalmology and consumer health product lines. Regional peer comparable to NovaCell given overlapping Korean ophthalmic market presence and similar pre-IPO/late-stage clinical development profile.

Emerging players

• RegeneRx Biopharmaceuticals: Clinical-stage peptide therapeutics company developing TB4-based treatments for ophthalmic and tissue repair indications. Emerging peer to NovaCell in the peptide-based ophthalmic biotherapeutics space with similar licensing-driven strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaCell Technology